Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Urinary Bladder Neoplasms 2Multiple Myeloma 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Squamous Cell 1

Interventions

Lenalidomide 8Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Leflunomide 2Cyclophosphamide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1PVX-410 vaccine 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × In Situ Hybridization, Fluorescence × 1 year × Clear all
NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
54 enrolled 13 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡